Schering Corporation

Merck Sharp + Dohme Corp.

Ahmed Samatar

Alan Cooper

Sunil Paliwal

Jagdish Desai

Hugh Zhu

Joseph Kelly

Hon-chung Tsui

Yiji Wu

M. Arshad Siddiqui

Alan Hruza

Azim A. Celebi

Sobhana Babu Boga

Li Xiao

Youhao Dong

Stuart W McCombie

Andrew William Stamford

Neng-Yang Shih

Joseph Michael Kelly

Yusheng Wu

Ronald J Doll

Vincent Stewart Madison

M Arshad Siddiqui

Alan B Cooper

Gerald Wayne Shipps, Jr

Alan W Hruza

Yongqi Deng

Robert Sun

Jagdish A Desai

James J-s Wang

Hugh Y Zhu

Tong Wang

Yang Nan

Ying Huang

Pauline C Ting

Eric J Gilbert

Xiaolei Gao

Hon-Chung Tsui

Ahmed Abdi Samatar

Mehul F Patel

Liang Zhu

Jianhua Cao

Gerald W Shipps

Abdul-Basit Alhassan

Azim Alan Celebi

Vincent S Madison

Jr Shipps Gerald W

Azim A Celebi

Ronald Doll

James Wang

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, R, X, X, R, R, R, R, R, Rand n are as defined in the specification.

Bipiperdine derivatives useful as CCR3 antagonists

The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.

Heteroaryl urea neuropeptide Y Y5 receptor antagonists

The present invention relates to compounds represented by the structural Formula I:or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.

Growing community of inventors

Cambridge, MA, United States of America

Youhao Dong